170 related articles for article (PubMed ID: 32457988)
1. Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features.
Roos-Weil D; Giacopelli B; Armand M; Della-Valle V; Ghamlouch H; Decaudin C; Metzner M; Lu J; Le Garff-Tavernier M; Leblond V; Vyas P; Zenz T; Nguyen-Khac F; Bernard OA; Oakes CC
Blood; 2020 Jul; 136(5):585-595. PubMed ID: 32457988
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.
Hunter ZR; Xu L; Yang G; Tsakmaklis N; Vos JM; Liu X; Chen J; Manning RJ; Chen JG; Brodsky P; Patterson CJ; Gustine J; Dubeau T; Castillo JJ; Anderson KC; Munshi NM; Treon SP
Blood; 2016 Aug; 128(6):827-38. PubMed ID: 27301862
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia.
Gayet M; Leymarie V; Derouault P; Guérin E; Vaidié J; Pascal V; Boulin M; Dmytruk N; Chauzeix J; Trimoreau F; Gachard N; Feuillard J; Rizzo D
Cytometry B Clin Cytom; 2022 Jan; 102(1):62-69. PubMed ID: 33634586
[TBL] [Abstract][Full Text] [Related]
4. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.
Hunter ZR; Yang G; Xu L; Liu X; Castillo JJ; Treon SP
J Clin Oncol; 2017 Mar; 35(9):994-1001. PubMed ID: 28294689
[TBL] [Abstract][Full Text] [Related]
5. Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia.
Hao M; Barlogie B; Tricot G; Liu L; Qiu L; Shaughnessy JD; Zhan F
Clin Cancer Res; 2019 Jan; 25(1):201-209. PubMed ID: 30279229
[TBL] [Abstract][Full Text] [Related]
6. The cellular origin and malignant transformation of Waldenström macroglobulinemia.
Paiva B; Corchete LA; Vidriales MB; García-Sanz R; Perez JJ; Aires-Mejia I; Sanchez ML; Barcena P; Alignani D; Jimenez C; Sarasquete ME; Mateos MV; Ocio EM; Puig N; Escalante F; Hernández J; Cuello R; García de Coca A; Sierra M; Montes MC; González-López TJ; Galende J; Bárez A; Alonso J; Pardal E; Orfao A; Gutierrez NC; San Miguel JF
Blood; 2015 Apr; 125(15):2370-80. PubMed ID: 25655603
[TBL] [Abstract][Full Text] [Related]
7. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
[TBL] [Abstract][Full Text] [Related]
8. Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.
Poulain S; Roumier C; Galiègue-Zouitina S; Daudignon A; Herbaux C; Aiijou R; Lainelle A; Broucqsault N; Bertrand E; Manier S; Renneville A; Soenen V; Tricot S; Roche-Lestienne C; Duthilleul P; Preudhomme C; Quesnel B; Morel P; Leleu X
Am J Hematol; 2013 Nov; 88(11):948-54. PubMed ID: 23861223
[TBL] [Abstract][Full Text] [Related]
9. TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation.
Shrimpton J; Care MA; Carmichael J; Walker K; Evans P; Evans C; de Tute R; Owen R; Tooze RM; Doody GM
Blood Adv; 2020 Jun; 4(12):2821-2836. PubMed ID: 32574366
[TBL] [Abstract][Full Text] [Related]
10. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals.
Gutiérrez NC; Ocio EM; de Las Rivas J; Maiso P; Delgado M; Fermiñán E; Arcos MJ; Sánchez ML; Hernández JM; San Miguel JF
Leukemia; 2007 Mar; 21(3):541-9. PubMed ID: 17252022
[TBL] [Abstract][Full Text] [Related]
12. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.
Gachard N; Parrens M; Soubeyran I; Petit B; Marfak A; Rizzo D; Devesa M; Delage-Corre M; Coste V; Laforêt MP; de Mascarel A; Merlio JP; Bouabdhalla K; Milpied N; Soubeyran P; Schmitt A; Bordessoule D; Cogné M; Feuillard J
Leukemia; 2013 Jan; 27(1):183-9. PubMed ID: 22944768
[TBL] [Abstract][Full Text] [Related]
13. Detection of the MYD88
Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX
Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844
[TBL] [Abstract][Full Text] [Related]
14. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.
Hunter ZR; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Manning RJ; Tripsas C; Patterson CJ; Sheehy P; Treon SP
Blood; 2014 Mar; 123(11):1637-46. PubMed ID: 24366360
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing.
Shin DW; Kim SM; Kim JA; Park HS; Hwang SM; Im K; Kim S; Kim J; Kwon S; Yoon SS; Lee DS
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e496-e505. PubMed ID: 31221512
[TBL] [Abstract][Full Text] [Related]
16. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotypic analysis of Waldenstrom's macroglobulinemia.
San Miguel JF; Vidriales MB; Ocio E; Mateo G; Sánchez-Guijo F; Sánchez ML; Escribano L; Bárez A; Moro MJ; Hernández J; Aguilera C; Cuello R; García-Frade J; López R; Portero J; Orfao A
Semin Oncol; 2003 Apr; 30(2):187-95. PubMed ID: 12720134
[TBL] [Abstract][Full Text] [Related]
18. MYD88 L265P mutation in Waldenstrom macroglobulinemia.
Poulain S; Roumier C; Decambron A; Renneville A; Herbaux C; Bertrand E; Tricot S; Daudignon A; Galiègue-Zouitina S; Soenen V; Theisen O; Grardel N; Nibourel O; Roche-Lestienne C; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
Blood; 2013 May; 121(22):4504-11. PubMed ID: 23532735
[TBL] [Abstract][Full Text] [Related]
19. Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.
Varettoni M; Zibellini S; Capello D; Arcaini L; Rossi D; Pascutto C; Rattotti S; Mangiacavalli S; Pochintesta L; Gotti M; Gaidano G; Cazzola M
Leuk Lymphoma; 2013 Nov; 54(11):2485-9. PubMed ID: 23442064
[TBL] [Abstract][Full Text] [Related]
20. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma.
Chng WJ; Schop RF; Price-Troska T; Ghobrial I; Kay N; Jelinek DF; Gertz MA; Dispenzieri A; Lacy M; Kyle RA; Greipp PR; Tschumper RC; Fonseca R; Bergsagel PL
Blood; 2006 Oct; 108(8):2755-63. PubMed ID: 16804116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
